Sharing technical read on subject cancer-associated fibroblasts. Been the purpose of my supplements regieme, along with cancer stem cells, for past several years. My usPSA continues in very low stable range, 0.02X-0.03X for past three years. www.ncbi.nlm.nih.gov/pmc/articles/PMC7714988/?fbclid=IwAR36j4oZPa6nVhXemIbNyNJ4nabAAXIEjHMyiigr6F...Natural products remodel cancer-associated fibroblasts in desmoplastic tumors
www.ncbi.nlm.nih.gov
Desmoplastic tumors have an abundance of stromal cells and the extracellular matrix which usually result in therapeutic resistance. Current treatment prescriptions for desmoplastic tumors are usually ...Remaining committed to strength maintenance in battle with remaining cancer/cancer stem cells. usPSA holding in very low stable range 0.02X-0.03X. In fifth year since third curative attempt with extended salvage lymph node disection. All the best to all of us!This content isn't available right now
When this happens, it's usually because the owner only shared it with a small group of people, changed who can see it or it's been deleted.We hear ‘a lot’ about exercise and cancer. I have shared a few photos of my trainer guided strength training; 1h/3X week. Plus a lot more. Sharing IMO an excellent podcast on this subject. Since I (significantly) stepped it up a year ago my fitness strength advancements exceed my expectations given three curative attempts and a year of ADT as added insurance. Most grateful my cancer remains at very very low stable usPSA levels - 0.02X-0.03X. All the best to all of us.#250 ‒ Training principles for longevity | Andy Galpin, Ph.D. (PART II) - Peter Attia
bit.ly
“The best marathoners in the world would smash almost everyone you know in a 100-meter dash. They're blazingly fast.” —Andy GalpinFollow-up to my previous post about the new-to-me Guardant360 'blood biopsy'. Combined with my dropping usPSA, March result down to 0.027, this report summary is most encouraging: "No reportable tumor-related somatic alterations were detected in this patient's sample. This may be due to either absence of reportable mutations in the tumor itself or low levels of circulating tumor-derived cell-free DNA (ctDNA). Low ctDNA levels are most often encountered in patients with early stage or low volume disease, patients responding to therapy, and/or patients with stable disease". Best to all!
